This cluster includes studies exploring the synergistic effects of combining PD-1 with GITR-targeted immunotherapy to restore CD8+ T cell functionality and maintain memory phenotypes, underscoring the potential of combinatorial approaches to enhance anti-tumor immunity. The gene discussed is TNFRSF18; the disease is neoplasm.